MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
17.88
-1.06
-5.60%
After Hours: 18.05 +0.17 +0.95% 19:19 03/27 EDT
OPEN
18.83
PREV CLOSE
18.94
HIGH
18.84
LOW
17.66
VOLUME
1.74M
TURNOVER
--
52 WEEK HIGH
19.67
52 WEEK LOW
4.700
MARKET CAP
1.78B
P/E (TTM)
-8.6902
1D
5D
1M
3M
1Y
5Y
1D
A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline
Simply Wall St · 1d ago
Definium Therapeutics to host Investor and Analyst Day; DT120 ODT Phase 3 program to be highlighted
Reuters · 3d ago
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
Barchart · 3d ago
How Investors May Respond To Definium Therapeutics (DFTX) Completing Phase III DT120 Enrollment In Depression
Simply Wall St · 4d ago
Weekly Report: what happened at DFTX last week (0316-0320)?
Weekly Report · 6d ago
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum
Simply Wall St · 03/21 10:09
Is It Too Late To Consider Definium Therapeutics (DFTX) After A 163% One Year Surge?
Simply Wall St · 03/19 21:09
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
The Motley Fool · 03/18 15:34
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.